SuperworthAcadia Pharmaceuticals profit margin ACAD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2011.
- Net margin, 12 months
- 33.4%
- Operating margin, 12 months
- 7.6%
- Net margin on a year earlier
- +11.6 pts
- Peer median
- 17.2%
Over the twelve months to Jun 30, 2026, Acadia Pharmaceuticals kept 33.4% of its revenue as net profit, with an operating margin of 7.6% and a gross margin of 91.1%.
Five years earlier its net margin was −56.5%.
The median for 10 large drugmakers of a similar size is 17.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 36.5% | 9.8% | 91.7% |
| FY2024 | 23.6% | 24.1% | 91.5% |
| FY2023 | −8.4% | −10.1% | 94.3% |
| FY2022 | −41.8% | −43.2% | 98.0% |
| FY2021 | −34.7% | −35.2% | 97.8% |
| FY2020 | −63.7% | −64.9% | 97.7% |
| FY2019 | −69.4% | −72.7% | 96.7% |
| FY2018 | n/a | n/a | 94.5% |
| FY2017 | n/a | n/a | 92.7% |
| FY2016 | n/a | n/a | n/a |
| FY2015 | n/a | n/a | n/a |
| FY2014 | n/a | n/a | n/a |
| FY2013 | n/a | n/a | n/a |
| FY2012 | n/a | n/a | n/a |
| FY2011 | n/a | n/a | n/a |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 33.4% | +11.6 pts | 7.6% | |
| Q1 FY26 | 34.3% | +11.3 pts | 7.4% | |
| Q4 FY25 | 36.5% | +12.8 pts | 9.8% | |
| Q3 FY25 | 24.9% | +11.1 pts | 23.0% | |
| Q2 FY25 | 21.8% | +18.4 pts | 23.2% | |
| Q1 FY25 | 23.0% | +23.2 pts | 23.6% | |
| Q4 FY24 | 23.6% | +32.1 pts | 24.1% | |
| Q3 FY24 | 13.8% | +37.4 pts | 12.1% | |
| Q2 FY24 | 3.4% | +23.5 pts | 2.6% | |
| Q1 FY24 | −0.2% | +27.8 pts | −0.6% | |
| Q4 FY23 | −8.4% | +33.3 pts | −10.1% | |
| Q3 FY23 | −23.5% | +18.9 pts | −24.4% |
Against its peers
Companies in Drug Manufacturers - General nearest Acadia Pharmaceuticals' size, closest first, today.
| Company | Profit margin |
|---|---|
| ACADAcadia Pharmaceuticals | 33.4% |
| OGNOrganon | 3.4% |
| LQDALiquidia | 30.7% |
| ARQTArcutis Biotherapeutics | 6.1% |
| INDVIndivior Pharmaceuticals | 26.7% |
| NRIXNurix Therapeutics | 42.0% |
| PBHPrestige Consumer Healthcare | 15.6% |
| HRMYHarmony Biosciences | 18.9% |
| KNSAKiniksa Pharmaceuticals International | 9.6% |
| LGNDLigand Pharmaceuticals | 67.9% |
| AMRXAmneal Pharmaceuticals | 5.0% |
| Peer median | 17.2% |
Where Acadia Pharmaceuticals ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Acadia Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.